259 related articles for article (PubMed ID: 24333184)
1. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
Younossi ZM; Stepanova M; Henry L; Gane E; Jacobson IM; Lawitz E; Nelson D; Nader F; Hunt S
J Hepatol; 2014 Apr; 60(4):741-7. PubMed ID: 24333184
[TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
Sirinawasatien A; Techasirioangkun T
PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
[TBL] [Abstract][Full Text] [Related]
3. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.
Younossi ZM; Stepanova M; Nader F; Lam B; Hunt S
Aliment Pharmacol Ther; 2015 Aug; 42(3):286-95. PubMed ID: 26059536
[TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Rodriguez-Torres M; Lawitz E; Kowdley KV; Nelson DR; Dejesus E; McHutchison JG; Cornpropst MT; Mader M; Albanis E; Jiang D; Hebner CM; Symonds WT; Berrey MM; Lalezari J
J Hepatol; 2013 Apr; 58(4):663-8. PubMed ID: 23183528
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
Younossi ZM; Stepanova M; Henry L; Han KH; Ahn SH; Lim YS; Chuang WL; Kao JH; Nguyen KV; Lai CL; Chan HL; Wei L
J Viral Hepat; 2018 Dec; 25(12):1429-1437. PubMed ID: 29974665
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL
J Hepatol; 2014 Aug; 61(2):228-34. PubMed ID: 24713186
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
Yin S; Barker L; White JZ; Jiles RB
J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL
Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Lawitz E; Poordad F; Brainard DM; Hyland RH; An D; Dvory-Sobol H; Symonds WT; McHutchison JG; Membreno FE
Hepatology; 2015 Mar; 61(3):769-75. PubMed ID: 25322962
[TBL] [Abstract][Full Text] [Related]
10. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
[TBL] [Abstract][Full Text] [Related]
11. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
Stepanova M; Nader F; Cure S; Bourhis F; Hunt S; Younossi ZM
Aliment Pharmacol Ther; 2014 Sep; 40(6):676-85. PubMed ID: 25040192
[TBL] [Abstract][Full Text] [Related]
12. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.
Mangia A; Piazzolla V
Dig Liver Dis; 2014 Dec; 46 Suppl 5():S179-85. PubMed ID: 25458780
[TBL] [Abstract][Full Text] [Related]
13. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
14. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
Shin HP; Burman B; Kozarek RA; Zeigler A; Wang C; Lee H; Zehr T; Edwards AM; Siddique A
Gut Liver; 2017 Sep; 11(5):711-720. PubMed ID: 28651301
[TBL] [Abstract][Full Text] [Related]
15. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
[TBL] [Abstract][Full Text] [Related]
16. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
[TBL] [Abstract][Full Text] [Related]
17. [QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice].
Aimono Y; Kohyama N; Kamoshida T; Yamamoto T; Kogo M
Yakugaku Zasshi; 2019; 139(11):1427-1434. PubMed ID: 31685739
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
[TBL] [Abstract][Full Text] [Related]
20. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
Dolatimehr F; Karimi-Sari H; Rezaee-Zavareh MS; Alavian SM; Behnava B; Gholami-Fesharaki M; Sharafi H
Daru; 2017 Apr; 25(1):11. PubMed ID: 28427463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
